Abstract 2453
Background
Recent development in cancer care challenges the earlier and more linear care trajectory. This implies an increased need for symptom management and support. In research on intensity of care at end-of-life (EOL), there is a trend to increased utilization of health, such as re-admissions, emergency admissions and to intensive care (ICU). Previous research has investigated factors such as gender, socio-economic status, comorbidities and type of disease. Research on symptoms leading to hospitalizations reveal that more than half of symptoms were related to disease and 30% to side-effects from treatment. Some research reveals that symptom burden in hospitalized patients may be associated with hospital length of stay (LOS) and re-admissions. This study aims to analyze the relationship between Health-Related Quality of Life (HRQoL) and different aspects of health care utilization, such as; LOS, re-admissions within 30 days and unplanned care.
Methods
Survey data using the European Organization for Research and Treatment of Cancer (EORTC QLQ C30) tool on HRQoL were linked data from the Swedish Cancer Quality registries and the database for health care utilization. Patients with a complex care trajectory (in this study Gynecology, Head & Neck, Hematology and Upper GI cancer) were included. Functional scales and symptom scales from EORTC QLQ C30 were analyzed for correlations with LOS, re- admissions within 30 days and unplanned care. Independent variables are patient demographics and clinical variables such as; treatment and/or type of treatment, performance status, co-morbidities and referral to palliative care.
Results
In total, 1872 patients responded to the survey (response rate 64 %), 41 % men and 59 % women (mean age 67 years). The number of patients in each group are; Gynecological (n 598), Hematological (n 461), Head & Neck (n 395) and Upper GI cancers (n 418). Analysis are currently ongoing with multivariate regression models and will be presented in the poster/oral presentation.
Conclusions
On possible correlations between different factors related to aspects of care utilization will be presented.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
This investigation and study was supported by grants from the Cancer Research Foundation in Northern Sweden.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
1908 - Androgen Receptor (AR) Aberrations in Patients (Pts) With Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Treated With Apalutamide (APA) Plus Androgen Deprivation Therapy (ADT) in TITAN
Presenter: Kim Chi
Session: Poster Display session 3
Resources:
Abstract
4058 - 68Ga-PSMA guided bone biopsies for molecular diagnostics in metastatic castration resistant prostate cancer patients
Presenter: Anouk de Jong
Session: Poster Display session 3
Resources:
Abstract
2226 - Spatial-Temporal Change in Quantitative Total Bone Imaging (QTBI) and Circulating Tumor Cells (CTCs) in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide (ENZA)
Presenter: Glenn Liu
Session: Poster Display session 3
Resources:
Abstract
5795 - Efficacy of Enzalutamide in Hormone-sensitive Metastatic Prostate Cancer: Clinical Utility of 18F-Choline PET and Whole Body MRI.
Presenter: Susanne Osanto
Session: Poster Display session 3
Resources:
Abstract
899 - Urine extracellular vesicle GATA2 mRNA alone and in a multigene test predicts initial prostate biopsy result
Presenter: Jungreem Woo
Session: Poster Display session 3
Resources:
Abstract
3094 - Circulating tumor cell (CTC) genomic landscape in neuroendocrine prostate cancer (NEPC) by single cell copy number analysis
Presenter: Vincenza Conteduca
Session: Poster Display session 3
Resources:
Abstract
2527 - Circulating Tumor Cells (CTC) count and Prostate-Specific Antigen (PSA) response measures in metastatic Castration-Resistant Prostate Cancer (mCRPC) patients (pts) treated with Docetaxel (Doc)
Presenter: Rebeca Lozano Mejorada
Session: Poster Display session 3
Resources:
Abstract
6106 - Assessing the clinical relevance of drug–drug interactions (DDI) with darolutamide (DARO)
Presenter: Christian Zurth
Session: Poster Display session 3
Resources:
Abstract
2237 - KEYNOTE-921: phase 3 study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone (abi)-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Presenter: Daniel Petrylak
Session: Poster Display session 3
Resources:
Abstract
2241 - KEYNOTE-641: Phase 3 Study of Pembrolizumab (pembro) Plus Enzalutamide for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Presenter: Julie Graff
Session: Poster Display session 3
Resources:
Abstract